PDCD1 and head and neck squamous cell carcinoma: Nivolumab and pembrolizumab, two monoclonal antibodies targeting the programmed cell death protein 1 (PD-1), received Food and Drug Administration approval in 2016 and 2019, respectively, for the palliative treatment of R/M HNSCC [5,6].